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I. INTRODUCTION
Medical progress in America is driven by innovation. Nevertheless,
throughout American history, many have died as a result of human
experimentation performed under the guise of innovation. Although the
Food and Drug Administration (“FDA”) can easily regulate drugs,
regulating physicians is a much more daunting task. Under current law, a
doctor may try any treatment, regardless of whether it is objectively
reasonable, as long as the doctor first obtains the patient’s informed
consent.1 The purpose of this Comment is to demonstrate that a patient’s
informed consent is an inadequate protection from harm and a new rule,
the reasonable innovation rule, must be codified. Codification of the
reasonable innovation rule will balance the dual goals of medical
innovation and patient protection.
First, a preliminary explanation of the reasonable innovation rule is
required. Ordinarily, customary care, the standard practice established in
the medical field in any given jurisdiction, meets the needs of most
1. K.H. Satyanarayana Rao, Informed Consent: An Ethical Obligation or Legal
Compulsion?, 1 J. CUTANEOUS & AESTHETIC SURGERY 33, 33 (2008), available at
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2840885/. Informed consent hinges on the ethical
principle of autonomy, which is the patient’s right to decide what happens to his or her body. Id.
Informed consent can either be express or implied. Id.; see also Bryan Murray, Informed Consent:
What Must a Physician Disclose to a Patient?, 14 VIRTUAL MENTOR 563, 563 (2012), available at
http://virtualmentor.ama-assn.org/2012/07/hlaw1-1207.html. Prior to obtaining informed consent,
physicians must explain any risks and benefits, as well as any information a reasonable person
would find important to the decision-making process. Id.
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patients.2 Under the reasonable innovation rule, if customary care is
unlikely to provide adequate treatment for one particular patient, a
doctor may innovate to meet the patient’s unique needs.3 The rule
demands that the innovative procedure be thoroughly researched before
being implemented.4 In other words, a physician may not implement any
treatment, only one that is reasonable. “Reasonableness” is a higher
standard than “informed consent” because it mandates a shared
responsibility between doctor and patient to engage only in treatments
that are considered objectively reasonable. This shifts some of the
burden currently pressuring patients to consent to risky, inadequately
researched procedures suggested by their physicians.5
Part II of this Comment will examine the history of human
experimentation and how the current regime of experimenting developed
then explore the gap between experimentation approved by an
Institutional Review Board (“IRB”)6 and FDA oversight. Part III will
consider the competing interests of individual patient protection and
medical innovation in general and whether informed consent
appropriately balances those interests. Part IV will evaluate the
inadequacies of current reliance on informed consent by using two case
studies, both involving novel microbial procedures, and discuss how
codification of the reasonable innovation rule would address those
inadequacies.
The two case studies involve (1) fecal microbiota transplants, which
have been highly successful,7 and (2) bacterial transplants performed in
2. 1 STEVEN E. PEGALIS, AMERICAN LAW OF MEDICAL MALPRACTICE § 3.3 (3d ed. rev.
2014).
3. Brook v. St. John’s Hickey Mem’l Hosp., 380 N.E.2d 72, 76 (Ind. 1978).
4. Id.
5. Nancy M. Kettle, Informed Consent: Its Origins, Purpose, Problems, and Limits 64-65
(Aug. 9, 2002) (unpublished Master thesis, University of South Florida), available at
http://scholarcommons.usf.edu/cgi/viewcontent.cgi?article=2522&context=etd.
6. Institutional Review Boards Frequently Asked Questions, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/regulatoryinformation/guidances/ucm126420.htm (last updated June 25, 2014)
[hereinafter IRB FAQs]. “Under FDA regulations, an IRB is an appropriately constituted group that
has been formally designated to review and monitor biomedical research involving human subjects.
In accordance with FDA regulations, an IRB has the authority to approve, require modifications in
(to secure approval), or disapprove research. This group review serves an important role in the
protection of the rights and welfare of human research subjects. The purpose of IRB review is to
assure, both in advance and by periodic review, that appropriate steps are taken to protect the rights
and welfare of humans participating as subjects in the research. To accomplish this purpose, IRBs
use a group process to review research protocols and related materials (e.g., informed consent
documents and investigator brochures) to ensure protection of the rights and welfare of human
subjects of research.” Id.
7. Maryn McKenna, Swapping Germs: Should Fecal Transplants Become Routine for
Debilitating Diarrhea?, SCI. AM. (Dec. 6, 2011), http://www.scientificamerican.com/
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an attempt to cure brain cancer, which had deadly consequences.8 In
both cases, as with human experimentation as a whole, informed consent
played a crucial role. These cases, however, also raise the question
whether consent should bar recovery. Vulnerable, ill patients may
consent to dangerous experiments out of desperation. The inadequacies
of informed consent will be discussed with this in mind.
Ultimately, this Comment will argue that the common law
reasonable innovation rule must be codified to protect vulnerable
patients who are willing to try anything. Current oversight and
regulation of physicians who implement novel treatments on a regular
basis do not offer enough protection to the desperate patient. It is time
for the FDA to intervene in our current “wild west” system where
physicians are free to deviate from common practice and implement
novel and even dangerous procedures as long as they obtain patients’
informed consent.
The FDA must take action by incorporating the reasonable
innovation rule into federal regulations instead of leaving it hidden in
case law. This will set a minimum standard for physicians who wish to
integrate novel treatments into everyday practice. Codifying the rule will
not unreasonably restrict innovation because physicians will be able to
try new procedures that meet patients’ unique needs, provided the
procedures are well researched and reasonable.
II. REGULATION IN THE UNITED STATES: A BACKGROUND
A.

The History of Human Experimentation Without Regulation

America has a dark history of human experimentation, even within
the past 100 years.9 This Comment maintains it is futile to believe that
vulnerable populations can always provide true informed consent for
treatment using experimental procedures. It asserts, instead, that the
obtaining of informed consent for experimental treatment from certain
patients, including those who are terminally ill, near death, and for
whom approved treatments have failed, is problematic. The practice, in
fact, provides disconcerting parallels, though on an individual basis, to
article.cfm?id=swapping-germs.
8. See Marjie Lundstrom, UC Davis Surgeons Resign After Bacteria-in-Brain Dispute,
SACRAMENTO
BEE,
http://www.sacbee.com/2013/08/25/5678851/uc-davis-surgeons-resignafter.html (updated Oct. 6, 2014, 2:38 PM).
9. Mike Stobbe, Ugly Past of US Human Experiments Uncovered, NBC NEWS,
http://www.nbcnews.com/id/41811750/ns/health-health_care/#.UtLxOfRDua8 (last updated Feb.
27, 2011, 6:14 PM).
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prior human experimentation that we now consider unethical,
regrettable, and of little benefit to the subjects involved.
Several case studies regarding medical research undertaken by
American researchers involving human subjects demonstrate how
vulnerable individual patients can be and support this Comment’s thesis
that regulation is essential to protect patients even from well-intentioned
researchers. For instance, in 1932, the Public Health Service began an
experiment called the “Tuskegee Study of Untreated Syphilis in the
Negro Male.”10 The purpose of this study was to determine how syphilis
affected African Americans as opposed to Caucasians.11 The theory of
the experiment was that Caucasians experienced more neurological
complications from syphilis while African Americans experienced more
cardiovascular complications.12 How the results of the study would be
used in clinical treatment remains unclear.13
This study had several problems. First, it lacked adequate informed
consent.14 Rather than revealing the true purpose of the experiment (to
record the “natural history of syphilis in Blacks”),15 the researchers
informed the 600 participants, who were all black men, that they were
being treated for “bad blood.”16 “Bad blood” was a colloquial expression
used to describe a variety of illnesses such as anemia, fatigue, and
syphilis.17 The researchers did not disclose the study’s true purpose
because they wanted to ensure cooperation.18 Furthermore, although no
proven treatments for the disease existed when the study commenced,
penicillin was found to be an effective treatment in 1947.19 Nevertheless,
the researchers withheld this treatment from the participants.20 This
study, which was projected to last a short six months, actually continued
for forty years.21 As a result, 28 men died from syphilis, 100 men died

10. The Tuskegee Timeline, CTRS. FOR DISEASE CONTROL & PREVENTION,
http://www.cdc.gov/tuskegee/timeline.htm (last updated Sep. 24, 2013).
11. Borgna Brunner, The Tuskegee Syphilis Experiment, INFOPLEASE (2007),
http://www.infoplease.com/spot/bhmtuskegee1.html.
12. Id.
13. Id.
14. Id.
15. About the USPHS Syphilis Study, TUSKEGEE UNIV., http://www.tuskegee.edu/about_us/
centers_of_excellence/bioethics_center/about_the_usphs_syphilis_study.aspx (last visited Jan. 7,
2014).
16. Id.
17. Id.
18. Brunner, supra note 11.
19. The Tuskegee Timeline, supra note 10.
20. Id.
21. Id.
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from related complications, 40 men infected their wives, and 19 of their
children were born with congenital syphilis.22
Another flagrant example of human experimentation involved the
discovery and development of penicillin in the mid-1900s.23 From 1946
to 1948, American public health doctors deliberately infected over 1,600
Guatemalans aged 10 to 72—prison inmates, children, mental patients,
female prostitutes, and soldiers—with venereal diseases in order to test
the efficacy of penicillin in treating or preventing sexually transmitted
diseases.24 In total, 696 were infected with syphilis, 772 with gonorrhea,
and 142 with chancres.25 After subjects contracted the disease, they were
given penicillin.26 Not surprisingly, the research failed to yield any
medically useful information.27 The study was well hidden and came to
light only in 2011 when it was revealed that 83 of these patients died as
a result of the experiment.28
During the same time, American doctors were performing another
human experiment in Guatemala.29 They injected seven women,
residents of a Guatemalan insane asylum, with syphilis in the back of the
skull.30 The researchers hoped the syphilis infection would cure epilepsy,
but instead, the women contracted bacterial meningitis, probably due to
unsterilized injection needles.31
The 1940s through 1950s saw massive growth in the
pharmaceutical industry, and as a result, the government and private

22. Brunner, supra note 11.
23. Donald G. McNeil, Jr., U.S. Apologizes for Syphilis Tests in Guatemala, N.Y. TIMES
(Oct.1, 2010), http://www.nytimes.com/2010/10/02/health/research/02infect.html?_r=0; see also
Mariano Castillo, Guatemalans to File Appeal Over STD Experiments, CNN (June 15, 2012),
http://www.cnn.com/2012/06/15/us/guatemala-std-experiments/index.html.
24. Castillo, supra note 23. Shockingly, “American tax dollars, through the National
Institutes of Health, even paid for syphilis-infected prostitutes to sleep with prisoners, since
Guatemalan prisons allowed such visits. When the prostitutes did not succeed in infecting the men,
some prisoners had the bacteria poured onto scrapes made on their penises, faces or arms, and in
some cases it was injected by spinal puncture.” McNeil, supra note 23; see also Kara Rogers,
Guatemala Syphilis Experiment, ENCYCLOPÆDIA BRITANNICA, http://www.britannica.com/
EBchecked/topic/1805220/Guatemala-syphilis-experiment (last visited Feb. 21, 2014).
25. Castillo, supra note 23.
26. Id.
27. Shocking New Details of US STD Experiments in Guatemala, ASSOCIATED PRESS, Aug.
30, 2011, available at http://www.theguardian.com/world/2011/aug/30/guatemala-experiments.
28. Id.; see also Susan Donaldson James, Syphilis Experiments Shock, But So Do Third
World Drug Trials, ABC NEWS (Aug. 30, 2011), http://abcnews.go.com/Health/guatemala-syphilisexperiments-shock-us-drug-trials-exploit/story?id=14414902.
29. Id.
30. Id.
31. Id.
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corporations began to fund prisoner experimentation.32 “By the 1960s, at
least half the states allowed prisoners to be used as medical guinea
pigs.”33 It was not until 1978 that the FDA stepped in to regulate human
experiments conducted on prisoners.34 These examples of horrific
medical research performed on human subjects demonstrate that strict
regulations designed to protect people who are participating in a study,
or any type of experimental treatment, are necessary.
B.

Experimental Treatment and the FDA: The Space Between

This Comment argues that, while strong statutory protections are in
place for human subjects, oversight by the FDA is lacking. Because of
the gaps in oversight, it is inevitable that some vulnerable patients are
being subjected to inappropriate experimental treatment. First, a
preliminary explanation of the origin of statutory protections is required.
Next, the intricacies of the FDA drug approval process will be detailed,
and the FDA’s control over IRBs will be scrutinized. Finally, because of
a lack of oversight of IRBs, patients have relied on tort law and medical
malpractice actions to encourage physicians to use appropriate care in
suggesting experimental treatments. Thus, a brief explanation of medical
malpractice is provided for understanding the basis of those claims.
1. The Origin of Statutory Protections
Most of the basic regulations concerning human subject research
come from the Department of Health and Human Services (“DHHS”).35
The DHHS is a cabinet-level department of the federal government that
includes 11 agencies.36 The FDA, one of the DHHS agencies, is tasked
32. Stobbe, supra note 9.
33. Id. “Holmesburg Prison in Philadelphia made extensive use of inmates for medical
experiments. Some of the victims are still around to talk about it. Edward ‘Yusef’ Anthony, featured
in a book about the studies, says he agreed to have a layer of skin peeled off his back, which was
coated with searing chemicals to test a drug. He did that for money to buy cigarettes in prison.” Id.
34. Prisoners in Clinical Trials, FIRST CLINICAL RES. (Nov. 21, 2007),
http://firstclinical.com/fdagcp/?show=2007/RE%20Prisoners%20in%20clinical%20trials&format=fulllist.
35. Regulations, DEPT. OF HEALTH & HUMAN SERV., http://www.hhs.gov/
ohrp/humansubjects/ (last visited Jan. 10, 2014). “In the United States, a series of highly publicized
abuses in research led to the enactment of the 1974 National Research Act (Public Law 93-348),
which created the National Commission for the Protection of Human Subjects of Biomedical and
Behavioral Research. One of the charges to the National Commission was to identify the basic
ethical principles that should underlie the conduct of biomedical and behavioral research involving
human subjects and to develop guidelines to assure that such research is conducted in accordance
with those principles.” Id.
36. About HHS, U.S. DEPT. OF HEALTH & HUMAN SERV., http://www.hhs.gov/about/ (last
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with regulating “clinical investigations of products under its jurisdiction,
such as drugs, biological products, and medical devices.”37 The FDA,
although under the DHHS umbrella, has its own specific rules for human
subject research to protect participants in the clinical trials of new drugs
and devices.38 Any variation between DHHS and FDA rules reflect
differences in the statutory scope or requirements.39
2. The Drug Approval Process
In response to a push for “legally mandated quality and identity
standards for food, prohibition of false therapeutic claims for drugs,
coverage of cosmetics and medical devices, clarification of the FDA’s
right to conduct factory inspections, and control of product advertising,”
Congress passed the 1938 Food, Drug, and Cosmetic Act (“FDCA”).40
One of the most important provisions of this law was a mandate that
drug manufacturers prove to the FDA that a drug is safe before it can be
sold on the market.41 This pre-market approval process forever changed
the way that drugs are regulated in the United States.42
The FDA drug approval process for both prescription and over-thecounter drugs involves several steps. First, after obtaining promising
clinical data, a drug manufacturer must apply for an Investigational New
Drug Application (“IND”) from the FDA’s Center for Drug Evaluation
and Research.43 After submitting an IND, a manufacturer must wait 30
days before beginning clinical trials44 to allow the FDA to research and
review the prospective study.45 “If [the] FDA finds a problem, it can
revised Oct. 6, 2014).
37. Regulations, supra note 35.
38. Comparison of FDA and HHS Human Subject Protection Regulations, U.S. FOOD &
DRUG
ADMIN.,
http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/
EducationalMaterials/ucm112910.htm (last updated Mar. 10, 2009).
39. Id.
40. The 1938 Food, Drug, and Cosmetic Act, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/aboutFDA/WhatWeDo/History/origin/ucm054826.htm (last updated Sep. 24,
2012).
41. Id.
42. Id.
43. How Drugs are Developed and Approved, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/de
fault.htm (last updated Feb. 13, 2014). The Center for Drug Evaluation and Research “is the largest
of FDA’s five centers. It has responsibility for both prescription and nonprescription or over-thecounter (OTC) drugs. The other four FDA centers have responsibility for medical and radiological
devices, food, and cosmetics, biologics, and veterinary drugs.” Id.
44. “Clinical trials are experiments that use human subjects to see whether a drug is effective,
and what side effects it may cause.” Id.
45. Id.
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order a ‘clinical hold’ to delay an investigation, or interrupt a clinical
trial if problems occur during the study.”46 After clinical trials are
complete and the manufacturer has determined that enough evidence
exists to meet the FDA’s standards, the manufacturer must then submit a
New Drug Approval Application (“NDA”).47 The NDA is a detailed
application containing information such as “manufacturing
specifications, stability and bioavailablility data, method of analysis of
each of the dosage forms the sponsor intends to market, packaging and
labeling for both physician and consumer, and the results of any
additional toxicological studies not already submitted.”48 Only after the
NDA is approved may the drug be placed on the market.49
3. Regulation of Institutional Review Boards
The FDA has the power to regulate not only drugs and devices but
also IRBs. “An IRB is an appropriately constituted group that has been
formally designated to review and monitor biomedical research
involving human subjects.”50 Under current law, the FDA requires
IRBs51 to “review and monitor biomedical research involving human
subjects.”52 Each IRB that oversees FDA-regulated studies must register
with the FDA.53 All IRBs must assure that each human subject has given
informed consent prior to commencement of the study.54
46. Id.
47. Id.
48. Id.
49. Id.
50. See IRB FAQs, supra note 6.
51. For a description of IRBs, see id.
52. See id.
53. Id.
54. Id. “The fundamental purpose of IRB review of informed consent is to assure that the
rights and welfare of subjects are protected. A signed informed consent document is evidence that
the document has been provided to a prospective subject (and presumably, explained) and that the
subject has agreed to participate in the research. IRB review of informed consent documents also
ensures that the institution has complied with applicable regulations.” Id. The FDA sets out the
following criteria for IRB approval of research in 21 C.F.R. § 56.111 (2013):
(a) In order to approve research covered by these regulations the IRB shall
determine that all of the following requirements are satisfied:
(1) Risks to subjects are minimized: (i) By using procedures which are
consistent with sound research design and which do not unnecessarily expose
subjects to risk, and (ii) whenever appropriate, by using procedures already
being performed on the subjects for diagnostic or treatment purposes.
(2) Risks to subjects are reasonable in relation to anticipated benefits, if any, to
subjects, and the importance of the knowledge that may be expected to result.
In evaluating risks and benefits, the IRB should consider only those risks and
benefits that may result from the research (as distinguished from risks and
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IRBs have incurred a lot of criticism through the years, but perhaps
the most serious concern is the FDA’s lack of oversight.55 In 2007, the
Office of the Inspector General stated that the FDA’s oversight of IRB
clinical trials was “weak, disorganized, and thus unable to ensure the
safety of clinical research participants.”56 The Office of the Inspector
General further noted the FDA could not possibly supervise all clinical
trials or IRBs tasked with overseeing the research involved in the trials
benefits of therapies that subjects would receive even if not participating in the
research). The IRB should not consider possible long-range effects of applying
knowledge gained in the research (for example, the possible effects of the
research on public policy) as among those research risks that fall within the
purview of its responsibility.
(3) Selection of subjects is equitable. In making this assessment the IRB should
take into account the purposes of the research and the setting in which the
research will be conducted and should be particularly cognizant of the special
problems of research involving vulnerable populations, such as children,
prisoners, pregnant women, handicapped, or mentally disabled persons, or
economically or educationally disadvantaged persons.
(4) Informed consent will be sought from each prospective subject or the
subject’s legally authorized representative, in accordance with and to the extent
required by part 50.
(5) Informed consent will be appropriately documented, in accordance with and
to the extent required by 50.27.
(6) Where appropriate, the research plan makes adequate provision for
monitoring the data collected to ensure the safety of subjects.
(7) Where appropriate, there are adequate provisions to protect the privacy of
subjects and to maintain the confidentiality of data.
(b) When some or all of the subjects, such as children, prisoners, pregnant
women, handicapped, or mentally disabled persons, or economically or
educationally disadvantaged persons, are likely to be vulnerable to coercion or
undue influence additional safeguards have been included in the study to
protect the rights and welfare of these subjects.
(c) In order to approve research in which some or all of the subjects are
children, an IRB must determine that all research is in compliance with part 50,
subpart D of this chapter.
55. David A. Hyman, Institutional Review Boards: Is This the Least Worst We Can Do?, 101
NW. U. L. REV. 749, 749 (2007). “Institutional Review Boards (‘IRBs’) are polarizing institutions.
IRB supporters view them as the best thing since sliced bread. Detractors believe IRBs impose costs
and have no benefits. Supporters point to the good faith and hard work of those who volunteer to
serve on an IRB. Detractors suggest that IRBs emphasize bureaucratic busy-work. Supporters ask
for more money and more staff so they can do an even more thorough job reviewing research
protocols. Detractors point out that the IRB framework of research oversight would never be
approved by an IRB. Supporters counter that notorious examples of abuse show that IRBs are
necessary. Detractors respond with anecdotes of IRB stupidity and incompetence. Supporters argue
that conducting research is a privilege, not a right. Detractors complain about censorship,
restrictions on academic freedom, and the chilling of constitutionally protected free speech. Both
sides then return to their respective camps, secure in the knowledge that they are right and those on
the other side are self-righteous zealots.” Id.
56. Jill Wechsler, FDA Hit for Poor Clinical Trial Oversight, SPECTROSCOPY (Nov. 1, 2007),
http://www.spectroscopyonline.com/spectroscopy/article/articleDetail.jsp?id=468088.
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because it “lacks an efficient information system for tracking clinical
research activity, site inspections, and resulting corrective actions.”57
The FDA, in fact, oversees less than 1% of all clinical trials.58 As a
consequence, patients may suffer serious delay in remedying issues that
may arise during a clinical trial.59 The FDA inspects less than 300 IRBs
each year, “partly because the agency has no complete IRB database and
thus cannot identify all review boards evaluating clinical trials for
regulated products.”60
4. Medical Malpractice
Given the FDA’s limited oversight of IRBs, patients have turned to
tort law and actions premised on lack of informed consent. “Medical
malpractice occurs when a health care provider renders treatment that
deviates from the accepted standard of practice in the medical
community.”61 In other words, the care the doctor provided did not meet
the level of care that should have been provided. Medical malpractice
claims may be based either on deficient care in providing medical
procedures or on failure to obtain informed consent prior to the
procedure. The standard of care differs by jurisdiction and custom.62 It
may be acceptable for a doctor to use a certain treatment in one locale
but not in another.63
Although the FDA cannot, and should not, micromanage all of the
doctors in the United States to ensure compliance with established rules
and regulations, these gaps in the oversight of medical care and research
are more troubling when viewed in light of patient vulnerability to
human experimentation. Understanding the FDA’s inability to oversee
clinical trials and experimental treatments provides background for this
57. Id.
58. Id.
59. Gardiner Harris, Report Assails F.D.A. Oversight of Clinical Trials, N.Y. TIMES (Sept.
28, 2007), http://www.nytimes.com/2007/09/28/health/policy/28fda.html?_r=3&.
60. See Wechsler, supra note 56.
61. Robert P. Valletti, The Difficulty of Medical Malpractice: Deviation from Standard of
Care, GINARTE (Oct. 13, 2012), http://www.ginarte.com/2012/10/difficulty-medical-malpracticedeviation-standard-care/.
62. Id. “A major obstacle in medical malpractice claims, however, is proving there was an
actual deviation from a standard of care because the medical community is replete with doctors who
render their own ‘opinion’ as to what the requisite level of care should have been. In laymen terms,
doctors give their opinions as to what procedures or treatment should have been done based on a
given set of facts surrounding a person’s symptoms, and since there is no ‘bright line’ rule about
what types of procedures or treatments should be given (hence why it is called a doctor’s ‘opinion’),
proving a deviation from the standard is difficult.” Id.
63. Id.
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Comment’s argument that mere informed consent is not a sufficient
safeguard for vulnerable patients.
III. THE PROBLEM WITH INFORMED CONSENT
Medicine naturally seeks to balance a procedure’s benefits against
its risks. Physicians and patients must constantly evaluate whether the
risks of a given treatment are worth its benefits. Requiring a patient’s
informed consent prior to a medical procedure attempts to protect both
parties from making the wrong decision; but informed consent is often
inadequate, given patients’ limited knowledge of medicine and their
level of desperation.64 The law of informed consent was not developed
to regulate use of experimental or innovative medicines or medical
procedures, but it has been pressed into service in these areas.
Accordingly, it provides an incomplete and often ineffectual solution.
A.

Should Informed Consent Bar Recovery?

The doctrine of informed consent is premised upon the fundamental
right of every person to determine what is done to his or her body in the
course of medical treatment.65 The patient must be provided with enough
information to make an informed decision regarding whether to accept
or decline treatment.66 The elements of informed consent67 include
64. See King & Moulton, infra note 70, at 430.
65. Russell G. Thornton, Informed Consent, BAYLOR UNIV. MED. CTR. (Apr. 2000),
available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1312305/.
66. Id.
67. 45 C.F.R. § 46 (2005) currently reads as follows:
§46.116 General requirements for informed consent.
Except as provided elsewhere in this policy, no investigator may involve a human being
as a subject in research covered by this policy unless the investigator has obtained the
legally effective informed consent of the subject or the subject’s legally authorized
representative. An investigator shall seek such consent only under circumstances that
provide the prospective subject or the representative sufficient opportunity to consider
whether or not to participate and that minimize the possibility of coercion or undue
influence. The information that is given to the subject or the representative shall be in
language understandable to the subject or the representative. No informed consent,
whether oral or written, may include any exculpatory language through which the subject
or the representative is made to waive or appear to waive any of the subject’s legal
rights, or releases or appears to release the investigator, the sponsor, the institution or its
agents from liability for negligence.
(a) Basic elements of informed consent. Except as provided in paragraph (c) or (d) of
this section, in seeking informed consent the following information shall be provided to
each subject:
(1) A statement that the study involves research, an explanation of the purposes of the
research and the expected duration of the subject’s participation, a description of the
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competence,
disclosure,
understanding,
voluntariness,
and
authorization.68 A physician must explain the risks and benefits, as well
as the purpose and duration of treatment, as part of the consent process.69
Physicians obtain informed consent70 prior to any procedure to safeguard
against legal liability.71
There are two types of informed consent prevalent in America
today.72 Approximately half of the states utilize a physician-based
standard where physicians are expected to inform the patient about the

procedures to be followed, and identification of any procedures which are experimental;
(2) A description of any reasonably foreseeable risks or discomforts to the subject;
(3) A description of any benefits to the subject or to others which may reasonably be
expected from the research;
(4) A disclosure of appropriate alternative procedures or courses of treatment, if any, that
might be advantageous to the subject;
(5) A statement describing the extent, if any, to which confidentiality of records
identifying the subject will be maintained;
(6) For research involving more than minimal risk, an explanation as to whether any
compensation and an explanation as to whether any medical treatments are available if
injury occurs and, if so, what they consist of, or where further information may be
obtained;
(7) An explanation of whom to contact for answers to pertinent questions about the
research and research subjects’ rights, and whom to contact in the event of a researchrelated injury to the subject; and
(8) A statement that participation is voluntary, refusal to participate will involve no
penalty or loss of benefits to which the subject is otherwise entitled, and the subject may
discontinue participation at any time without penalty or loss of benefits to which the
subject is otherwise entitled.
68. See Kettle, supra note 5, at 60.
69. Id.
70. Jaime S. King & Benjamin W. Moulton, Rethinking Informed Consent: The Case for
Shared Medical Decision-Making, 32 AM. J.L. & MED. 429, 430 (2006), available at
http://librarysource.uchastings.edu/repository/King/32AmJLMed429.pdf. The American Medical
Association explains that sufficient information sharing by the physician, including all probable
risks and benefits, is paramount in the process of obtaining adequate patient consent. W. Eugene
Basanta, Communicating with Dying Patients, Proceedings of the 18th World Congress on Medical
Law
1
(2010),
available
at
http://www.law.siu.edu/_common/documents/
publications/basanta/communicating-patients.pdf. The American Medical Association goes on to
explain, “The patient’s right of self-decision can be effectively exercised only if the patient
possesses enough information to enable an informed choice. The patient should make his or her own
determination about treatment. The physician’s obligation is to present the medical facts accurately
to the patient or to the individual responsible for the patient’s care and to make recommendations
for management in accordance with good medical practice. The physician has an ethical obligation
to help the patient make choices from among the therapeutic alternatives consistent with good
medical practice. Informed consent is a basic policy in both ethics and law that physicians must
honor.” Id.
71. Patient Consent, LAW, SCI. & PUB. HEALTH PROGRAM SITE, http://biotech.law.lsu.edu/
Books/aspen/Aspen-Patient.html (last visited Jan. 11, 2014).
72. King & Moulton, supra note 70, at 430.
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risks that a “reasonably prudent practitioner” would be aware of.73 The
other 23 states and the District of Columbia rely on a patient-based
standard where physicians are expected to inform patients about the risks
a “reasonable patient” would find valuable to the decision-making
process.74 Patients may bring a negligence action against a physician by
alleging that they did not receive adequate information before
consenting to the procedure.75 A finding of informed consent, however,
should not bar recovery when particular situations render the patient’s
consent inadequate.76
In addition to possible shortcomings in information provided by the
physician, other fundamental problems with informed consent must be
considered. For instance, patients tend to strongly believe that their
physician would not recommend anything unnecessary or ineffective.77
Patients may also struggle with information overload regarding the
treatment and non-treatment options provided by their physician.78 Most
patients are not familiar with medical terms and are unable to sift
through complex and technical scientific information to understand what
is important to their specific needs.79
Moreover, special consideration must be given to obtaining
informed consent from what the DHHS has termed “vulnerable

73. Id.; Richard Weinmeyer, Lack of Standardized Informed Consent Practices and Medical
Malpractice, 16 AM. MED. ASSOC. J. ETHICS 120, 121 (2014).
74. King & Moulton, supra note 70, at 430.
75. “The theory of negligence holds that the defendant is liable for a careless action or
omission when the defendant had an obligation toward the plaintiff and careless action or omission
causes an injury. The standard of reasonable care is the level of care that a common person would
view as proper conduct. On the other hand, the profession is the group that sets the standards for
determining the level of due care in professional negligence or malpractice. Medical malpractice
occurs when a physician violates the standard of due care, including an omission to properly
disclose information about a specific procedure. In case of physicians’ negligence in informed
consent, an action would have to show that a physician violated a duty of ‘due care to inform a
patient, that this breach resulted in a financially measurable injury, and that a reasonable person
would not have consented.’” Kettle, supra note 5, at 57-58. “Listing ‘informed consent’ as an
allegation of negligence, within a medical malpractice suit, often does not give rise to a plaintiff
being awarded damages as the lack of ‘informed consent’ alone is not a basis for neglect except
when the plaintiff can prove the decision to proceed, or not proceed, with a procedure would have
been made differently, and solely, upon the accurate facts of an informed consent, had it been given
prior to surgery.” Christine Cadena, Medical Malpractice and the Informed Consent Doctrine (Feb.
1, 2007), available at http://tinytuna.com/medical-malpractice-and-the-informed-consent-doctrine/.
76. See Kettle, supra note 5, at 69.
77. Patient Consent, supra note 71.
78. Kettle, supra note 5. Contributing to this problem is patients’ reliance on selective
perception, making it difficult to figure out when words have a “special meaning for them, when
preconceptions distort their processing of the information, and when other biases intrude.” Id. at 71.
79. Id. at 68.
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subjects.”80 Groups such as children, the undereducated, the mentally
handicapped, the terminally ill, and pregnant women are considered
vulnerable populations.81 The common thread among these groups is that
they may be more prone to coercion or undue influence while
participating in experimental treatment.82 The terminally ill, for example,
are of particular interest to this Comment. The patients in the brain
bacteria case, discussed in the following section, are considered a special
group because all three patients were terminally ill.83 Extra attention
must be given to the terminally ill because they may be willing to try
anything to improve their conditions and save their lives.84
80. DEPT. OF HEALTH & HUMAN SERV., INSTITUTIONAL REVIEW BOARD GUIDEBOOK, ch. 6,
available at http://www.hhs.gov/ohrp/archive/irb/irb_chapter6.htm (last updated 1993).
81. Id. Alarmingly, these special groups frequently suffer from institutional failures because
their unique needs are not adequately addressed prior to obtaining their informed consent. “In a
cross-sectional survey of IRBs in U.S. institutions, investigators showed that IRBs rarely or never
required procedures to determine capacity and also varied in their use of other safeguards, such as
independent monitors, research proxies, and advance research directives.” Henry Silverman,
Protecting Vulnerable Research Subjects in Critical Care Trials: Enhancing the Informed Consent
Process and Recommendations for Safeguards, ANNALS OF INTENSIVE CARE, 2011, at 1, available
at http://www.annalsofintensivecare.com/content/pdf/2110-5820-1-8.pdf. Although, the FDA has
made exceptions for the terminally ill: it allows for “compassionate use” of a drug for those who are
extremely desperate. “Expanded access,” sometimes called “compassionate use,” is the use of an
investigational drug outside of a clinical trial to treat a patient with a serious or immediately lifethreatening disease or condition who has no comparable or satisfactory alternative treatment
options. Expanded Access: Information for Patients, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/Ap
provalApplications/InvestigationalNewDrugINDApplication/ucm351748.htm (last updated Oct. 4,
2013). “FDA regulations allow access to investigational drugs for treatment purposes on a case-bycase basis for an individual patient, or for intermediate-size groups of patients with similar treatment
needs who otherwise do not qualify to participate in a clinical trial. They also permit expanded
access for large groups of patients who do not have other treatment options available, once more is
known about the safety and potential effectiveness of a drug from ongoing or completed clinical
trials.” Compassionate Use Programs, ALS ASSOC., http://www.alsa.org/als-care/resources/
publications-videos/factsheets/compassionate-use.html (last visited Feb. 24, 2015). “Just as in
clinical trials, these investigational drugs have not yet been approved by the FDA as safe and
effective. They may be effective in the treatment of a condition, or they may not. They also may
have unexpected serious side effects.” Id.
82. Univ. of South Fla. IRB Training, Identifying and Protecting Vulnerable Populations,
GEN.
HOSP.,
https://www.tgh.org/PDFs/
available
at
TAMPA
IdentifyingandProtectingVulnerablePopulations.pdf (last visited Nov. 16, 2014).
83. Marjie Lundstrom & Sam Stanton, Evaluation of UC Davis Medical Center’s Handling
BEE,
http://www.sacbee.com/2012/
of
Neurosurgeons
is
Scathing,
SACRAMENTO
12/23/5072625/evaluation-of-uc-davis-medical.html (updated Oct. 8, 2014, 10:39 AM).
84. Natalie L. Regoli, Insurance Roulette: The Experimental Treatment Exclusion &
Desperate Patients, 22 QUINNIPIAC L. REV. 697, 697 (2004). This article describes an archetypal
situation that closely mirrors the brain bacteria case. “During the last decade, the archetypal
experimental treatment lawsuit has been one in which a gravely-ill patient petitions the court for an
order directing his or her insurance company to authorize certain procedures. Such a case begins
after standard medical treatment has failed, and the patient’s treating physician recommends newer
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In summary, obtaining informed consent prior to an experimental
procedure is not a sufficient safeguard for vulnerable patients. The law
must intervene to protect patients who consent, as a last resort, to
experimental treatments that may be ineffective or even unsafe.85 This
gap between inadequate informed consent by desperate patients and the
need for medical innovation can be filled by codification of the
reasonable innovation rule.
B.

Autonomy Of Physician Decision Making

As demonstrated by the previous sections of this Comment,
regulation of medicine is necessary to protect patents. However,
physician autonomy is a major concern when it comes to regulation of
innovation and the medical profession. Advocates for greater physician
autonomy maintain that greater autonomy and fewer regulations promote
medical innovation.86 Each patient presents a unique situation where
physicians may need to implement new or different techniques to best
treat the patient.87 Excessive regulation and strict guidelines curb
creativity crucial to physicians and the medical profession as a whole.88
In order to attract talented professionals, the field of medicine must trust
physicians to self-regulate.89 Loss of autonomy is one of the most
common complaints of physicians who report feeling disenchanted with
their careers.90
Nonetheless, there must be a balance between regulation and
autonomy to protect patients from consenting to procedures that are not
yet approved for widespread use. The FDA continuously struggles with

treatments out of the belief that they are the best opportunity to sustain the patient’s health and life.
In the patient’s desperate efforts to procure whatever treatments may improve her condition, the
patient decides to assume the risk of these new treatments.” Id.
85. Id. at 699.
86. Richard L. Reece, Government Regulation and Physician Autonomy, MEDINNOVATION &
HEALTH REFORM (Apr. 1, 2010), http://medinnovationblog.blogspot.com/2010/04/thoughts-ongovernment-regulation-and.html.
87. Id.
88. Id. The article argues, “Physicians struggle to improve quality, safety and efficiency in an
imperfect world of clinical practice that is overwhelmed with information, laced with ambiguity and
plagued by deepening physician shortages. From an organizational perspective, they require
sufficient numbers of colleagues, a supportive infrastructure, adequate reimbursement and freedom
from administrative and regulatory intrusion. High quality care depends on the autonomous exercise
of clinical judgment by competent and empathic physicians who are accountable to their patients
and society. No amount of regulation or incentives can substitute.” Id.
89. David Orentlicher, The Influence of a Professional Organization on Physician Behavior,
57 ALB. L. REV. 583, 585 (1994).
90. Id.
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this balance in deciding when and how to regulate.91 As the fecal
transplant portion of this paper will demonstrate, the FDA is hesitant to
regulate when beneficial innovation is occurring. In that case, an
innovative procedure—a fecal transplant—is resulting in an unusually
high success rate: over 90% of patients who undergo the procedure
experience complete elimination of symptoms.92 Thus, the fine line
between experimentation and innovation is once again tested.
IV. UNDERSTANDING THE SOLUTION TO INADEQUATE INFORMED
CONSENT THROUGH CASE STUDIES
Now that this Comment has explored the problems with informed
consent, it will shift focus to the solution for inadequate informed
consent: codifying the reasonable innovation rule. This will be achieved
by exploring instances where doctors used novel microbial experimental
treatments that were not FDA-approved after obtaining informed
consent.
First, subsection A will present a preliminary explanation of the
microbiome. Next, subsections B and C will discuss two very different
studies involving the use of microbial transplants. In the first study,
surgeons introduced live bacteria to the brains of three patients in hopes
of curing brain tumors, but this had deadly consequences. In the second
study, physicians introduced healthy fecal bacteria to patients’ colons to
cure chronic diarrhea, and this treatment had a 90% success rate.
Subsection D will compare the two studies to demonstrate why informed
consent is an inadequate safeguard for vulnerable patients. Subsection E
will introduce the reasonable innovation rule and explore its scope by
comparing two cases. Subsection F will argue for codification of the
reasonable innovation rule. Finally, subsection G will propose language
for codification.
A.

Human Experimentation in the Context of the Microbiome

The human body has over ten times more “bugs”—microbes that
live in the guts, mouth, and skin—than human cells; the human body is
“vastly more microbe than human.”93 The microbiome was first
91. MICHAEL MANDEL, PROGRESSIVE POLICY INST., HOW THE FDA IMPEDES INNOVATION:
A CASE STUDY IN OVERREGULATION (2011), available at http://progressivefix.com/wpcontent/uploads/2011/06/06.2011-Mandel_How-the-FDA-Impedes-Innovation.pdf.
92. McKenna, supra note 7.
93. Karen Weintraub, Microbiome: How Bugs May Be Crucial to Your Health, BBC,
http://www.bbc.com/future/story/20120412-the-beasts-inside-you (last visited Nov. 16, 2014).
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discovered in 1683 when Antoine Van Leeuwenhoek scraped “gritty
matter” off of his teeth and analyzed it under a microscope.94 This
experiment and its findings made him the first person to conceptualize
bacteria in the mouth.95 Over the centuries, the microbiomes that play
such a crucial role in human health have remained mostly a mystery.96
This is largely because it was nearly impossible to isolate and cultivate
more than 95% of our microorganisms in simulated laboratory
conditions.97 However, recent advances in DNA sequencing have made
it possible to study microbiomes without cultivating them in a
laboratory.98 Now that science is beginning to understand the effect that
these microscopic bugs have on our health, coupled with the fact that a
viable means of studying microbiomes now exists, the need for
volunteer donors has skyrocketed.99 As science enters this new realm of
understanding how microscopic bugs interact with the human body and
how to use this knowledge to treat or cure existing disease, society must
decipher what constitutes innovative treatment and what constitutes
human experimentation.
Two case studies involving microbial experimentation illustrate the
conflict between the need for patient protection and the need for
innovative medicine. The first highlights the inadequacies of informed
consent, while the second demonstrates regulators’ hesitation to
intervene where innovation is occurring.
B.

The Bacterial Transplant Case

In 2010 and 2011, three seriously ill patients at UC Davis Medical
Center consented to have their skulls opened and live bacteria introduced
to their brains.100 Two highly regarded neurosurgeons believed that
introducing Enterobacter aerogenes101 to the patients’ brains would wipe
94. Michael J. Cox, William O.C.M. Cookson & Miriam F. Moffat, Sequencing the Human
Microbiome in Health and Disease, 22 HUMAN MOLECULAR GENETICS R88, R88 (2013), available
at http://hmg.oxfordjournals.org/content/22/R1/R88.full.pdf.
95. Id.
96. Weintraub, supra note 93.
97. The Human Microbiome Project, BAYLOR COLL. OF MED., https://www.bcm.edu/
departments/molecular-virology-and-microbiology/research/the-human-microbiome-project
(last
visited Nov. 16, 2014).
98. Id.
99. Faith Rohlke & Neil Stollman, Fecal Microbiota Transplantation in Relapsing
Clostridium Difficile Infection, 5 J. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY 403, 403
(2012).
100. See Lundstrom & Stanton, supra note 83.
101. Enterobacter
Aerogenes,
BIOQUELL,
http://www.bioquell.com/technology/microbiology/enterobacter-aerogenes/ (last visited Nov. 22,
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out the patients’ deadly glioblastomas after the bacteria colonized.102 All
three patients, however, died after their transplants.103 Two died from
entering a septic shock just 14 days after surgery, and the last patient
lived a year but had to endure several more painful procedures due to
surgical complications.104
The neurosurgeons were able to perform these procedures because
they obtained informed consent from all three patients.105 The consent
forms were a mere 300 words that took up just one page, warning the
patients of the procedure’s dangers.106 “‘There is no proof that such
treatment (for brain cancer) might be beneficial,’ the form read, ‘nor are
there animal data to support it.’”107 The form went on to detail the
consequences and risks of introducing the bacteria to the patients’
brains, including “paralysis, inability to speak or understand speech,
inability to swallow, vegetative state, coma or death.”108 The surgeon
later claimed that, when the patients gave their express informed
consent, they were all “of sound mind,” and “their disease did not affect
their judgment” or decision-making ability.109
The surgeons purchased the bacteria from a Virginia lab after the
FDA ordered rigorous animal testing before “contemplating the
bacteria’s use in live patients.”110 Despite this, in a desperate attempt to
prolong the patients’ lives, the neurosurgeons circumvented the FDA
and IRB regulations and approval and infected the patients.111 It was
reported that, after interviewing 27 doctors, nurses, and hospital staff, no
2013). Enterobacter aerogenes is commonly found in the human gastrointestinal tract. Enterobacter
http://cuverro.com/tested-proven-trusted/scientific-proof/epa-tests/
Aerogenes,
CUVERRO,
enterobacter-aerogenes (last visited Dec. 27, 2014).
102. Glioblastoma, AM. BRAIN TUMOR ASS’N, http://www.abta.org/understanding-braintumors/types-of-tumors/glioblastoma.html (last visited Nov. 22, 2013). “Glioblastomas are tumors
that arise from astrocytes—the star-shaped cells that make up the ‘glue-like,’ or supportive tissue of
the brain. These tumors are usually highly malignant (cancerous) because the cells reproduce
quickly and they are supported by a large network of blood vessels. . . . Glioblastoma can be
difficult to treat because the tumors contain so many different types of cells. Some cells may
respond well to certain therapies, while others may not be affected at all. This is why the treatment
plan for glioblastoma may combine several approaches.” Id.
103. Lundstrom, supra note 8.
104. Marjie Lundstrom, Impact, Ethics of Surgery Slammed, SACRAMENTO BEE,
http://www.sacbee.com/2013/02/11/5180237/impact-ethics-of-surgery-slammed.html (updated Oct.
6, 2014, 2:38 PM).
105. Lundstrom, supra note 8.
106. Lundstrom, supra note 104.
107. Id.
108. Id.
109. Id.
110. Id.
111. Id.
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one was willing or able to report unsafe care practices they witnessed.112
The hospital personnel trusted the neurosurgeons so much as to not
question the highly unusual procedure.113 Both neurosurgeons have since
resigned, and the families of the deceased patient-victims have settled
their claims against the university.114 Now, complex questions remain
“about the nature of consent, what constitutes research[,] and how to
safeguard vulnerable patients.”115
C.

The Fecal Transplant Case: An Increasingly Popular Cure for an
Old Problem116

Feces can save lives. Over 14,000 lives a year, to be exact.117 Once
one overcomes the initial “ick factor,” the prospect of safe, regulated,
extremely effective fecal microbiota transplants (“FMT’s”) can bring
hope to thousands of Americans who suffer from Clostridium difficile
(“C. diff”) infections. Earlier this year, the FDA announced that it would
require IND applications for fecal microbiota transplantations to treat C.
diff infections for purposes of patient safety.118 Shortly after the
announcement, primarily due to negative pushback from advocates of
FMT, the FDA backed away from regulating the procedure and decided
that it would no longer require a physician to submit an IND application
prior to performing a fecal transplant.119 Instead, the FDA’s draft
guidance merely requires physicians to obtain informed consent from
patients before they undergo the transplant.120 An examination of FMTs
demonstrates the FDA’s reluctance to step in when physicians push for
greater autonomy with respect to successful, novel treatments.
1. The Fecal Transplant Case
One-thousand seven-hundred years ago, a Chinese doctor first
112. Lundstrom & Stanton, supra note 83.
113. Id.
114. Lundstrom, supra note 8.
115. Id.
116. C. diff was discovered in 1935, yet scientists did not recognize it as the major cause of
antibiotic-associated diarrhea until 1978. Clostridium Difficile: An Intestinal Infection on the Rise,
HEALTH
PUBL’NS
(June
1,
2010),
HARVARD
http://www.health.harvard.edu/newsletters/Harvard_Mens_Health_Watch/2010/June/clostridiumdifficile-an-intestinal-infection-on-the-rise.
117. Clostridium Difficile Infection, CTRS. FOR DISEASE CONTROL & PREVENTION,
http://www.cdc.gov/hai/organisms/cdiff/cdiff_infect.html (last updated Mar. 1, 2013).
118. Investigational New Drug (IND) Application, infra note 168.
119. Gaffney, infra note 175.
120. Id.
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prescribed “drinking liquefied feces as a treatment for severe diarrhea
and food poisoning.”121 Subsequently, the use of fecal transplants was
limited to veterinary medicine where the practice has been performed for
over 100 years.122 The first human fecal transplant was mentioned in a
1958 case series123 where four patients were treated for their
pseudomembranous enterocolitis.124 It noted that three of the four
patients were in critical condition when the fecal enemas were
administered.125 Surprisingly, all four patients’ symptoms resolved
within hours of receiving the fecal transplant.126 The first case
confirming treatment of C. diff by means of a fecal microbiota transplant
was documented in 1983.127 The procedure, however, did not gain wide
acceptance in the medical community due to the lack of controlled
clinical trials.128
Thus, the notion of curing gastrointestinal problems with an FMT
was nearly unheard of in 2011 when 79-year-old Marion Browning, a
retired nurse, began suffering from painful, chronic diarrhea.129 This
ailment, which lasted nearly a year, occurred after she was prescribed
antibiotics to treat her diverticulitis.130 Unfortunately, the antibiotics also
121. Diane Suchetka, Ohio Hospitals Now Performing Fecal Transplants for Patients with
Stubborn Cases of C. diff, CLEVELAND PLAIN DEALER (Jul. 8, 2013, 6:20 AM),
http://www.cleveland.com/metro/index.ssf/2013/07/three_ohio_hospitals_now_perfo.html.
122. Lawrence J. Brandt, Fecal Transplantation for the Treatment of Clostridium Difficile
Infection, 8 J. GASTROINTESTINAL & HEPATOLOGY 191, 191 (2012), available at
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3365524/.
123. Ryan Jaslow, Fecal Transplants Beat Antibiotics for Curing Diarrhea Caused by C.
Difficile, CBS NEWS (Jan. 17, 2013, 11:10 AM), http://www.cbsnews.com/8301-204_16257564470/fecal-transplants-beat-antibiotics-for-curing-diarrhea-caused-by-c-difficile/.
124. Johan S. Bakken et al., Treating Clostridium Difficile Infection with Fecal Microbiota
Transplantation, 9 J. CLIN. GASTROENTEROLOGY & HEPATOLOGY 1044, 1044 (2011), available at
http://www.cghjournal.org/article/S1542-3565%2811%2900891-3/abstract.
“Pseudomembranous
colitis is inflammation of the colon that occurs in some people who have taken antibiotics.
Pseudomembranous colitis is sometimes called antibiotic-associated colitis or C. difficile colitis.
The inflammation in pseudomembranous colitis is almost always associated with an overgrowth of
the bacterium Clostridium difficile.” Pseudomembranous Colitis, MAYO CLINIC (Dec. 5, 2012),
http://www.mayoclinic.com/health/pseudomembranous-colitis/DS00797.
125. Bakken et al., supra note 124, at 1045.
126. Id.
127. Id.
128. B. Guo et al., Systematic Review: Faecal Transplantation for the Treatment of
Clostridium Difficile-Associated Disease, 35 ALIMENTARY PHARMACOLOGY & THERAPEUTICS 865,
873 (2012).
129. McKenna, supra note 7.
130. Id. Diverticulitis is a condition where “small pouches protrude from the walls of the
colon. . . . Diverticulosis itself is really not a problem, as the pouches themselves are harmless and
rarely cause symptoms. However, the situation becomes more serious if the pouches become
infected from, for example, stool getting trapped in the pouch.” Diverticulosis and Diverticulitis,
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killed the friendly bacteria in Browning’s intestines, allowing a toxinproducing bacteria, C. diff,131 to colonize and start “eating away at the
entire lining of her gut.”132 Browning spent months visiting different
doctors, searching for a cure.133 Each visit resulted in a stronger
antibiotic to attempt to cure the C. diff, and while her condition would
improve at first, the antibiotics were ultimately unable to eliminate all of
the infection.134 After four rounds of powerful antibiotics, Browning’s
gastroenterologist informed her that he tried everything he could and
referred her to Colleen Kelly, a clinical researcher at the medical school
at Brown University.135 Finally, a cure for Browning’s painful C. diff
was in sight.136 What Kelly proposed sounded both “logical and
strangely unmedical”:137 she wanted Browning to receive a fecal
transplant.138
Healthy intestinal bacteria usually maintain a balance with
pathogenic bacteria,139 but in fragile individuals such as children, the
elderly, or immunosuppressed people, the overuse of antibiotics can
cause overgrowth of C. diff.140 Once there is an overgrowth of C. diff.,
patients experience days of severe diarrhea, which is extremely
dehydrating and can result in death if the condition persists.141 In
Browning’s case, the powerful antibiotics prescribed to her upset the
healthy balance of intestinal bacteria, resulting in a severe case of C.

INT’L. FOUND. FOR FUNCTIONAL GASTROINTESTINAL DISORDERS, http://www.iffgd.org/site/gidisorders/other/diverticulosis (last modified Sept. 16, 2014, 10:40 AM) (adapted from IFFGD
Publication #153 by Cheri Smith, Medical Writer).
131. Clostridium Difficile Infection, supra note 117. C. diff causes inflammation of the colon
due to prolonged use of antibiotics. “The main clinical symptoms of C. difficile infection (CDI) are
watery diarrhea, fever, nausea, abdominal pain/tenderness, and loss of appetite. More serious
conditions can also result such as pseudomembranous colitis (inflammation of the colon),
perforations of the colon, and sepsis. It is possible to carry C. diff bacteria in your body but not
show any symptoms; this is called colonization. After treatment, repeat testing is not recommended
if the patient’s symptoms have resolved, since many patients remain colonized with the bacteria.”
Clostridium Difficile (C. Difficile) Infections, VA. DEPT. OF HEALTH, http://
www.vdh.virginia.gov/epidemiology/surveillance/hai/cdiff.htm (last updated Apr. 3, 2014).
132. McKenna, supra note 7.
133. Id.
134. Id.
135. Id.
136. Id.
137. Id.
138. Id. There are many names for fecal transplants. They are “variously called fecal
transplant, fecal bacteriotherapy or fecal flora reconstitution.” Id.
139. Id.
140. Clostridium Difficile Infection, supra note 117.
141. Id.
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diff.142 Kelly reasoned that, if she took a diluted stool sample from a
healthy donor, the good bacteria could recolonize in Browning’s
intestine and wipe out the infection.143 Browning, desperate to try
anything after enduring months of gut-wrenching diarrhea, chose her son
as her donor.144 Kelly diluted the sample and used colonoscopy
instruments to introduce the sample into Browning’s large intestine.145
The results were astounding: Browning’s diarrhea was completely
eliminated within two days and never recurred.146
2. Recent Developments in Fecal Transplants
Browning’s success story did not go completely unrecognized: “in
medical journals, about a dozen clinicians in the U.S., Europe, and
Australia have described performing fecal transplants on about 300 C.
difficile patients so far.”147 Although fecal transplants are not unheard
of, their success rate is.148 More than 90% of patients recover completely
after receiving a fecal transplant.149 This statistic is encouraging due to
an increased occurrence of C. diff since a new epidemic strain emerged
in 2004.150 As a result of the antibiotic resistant C. diff strain, cases of
those infected have “doubled from about 134,000 patients in 2000 to
291,000 patients in 2005.”151 Another study showed that mortality rates
have increased “fourfold, from 5.7 deaths per million in the general
population in 1999 to 23.7 deaths per million in 2004.”152 Furthermore,
not only does C. diff pose an alarming threat to human life, but it also

142. McKenna, supra note 7.
143. Id.
144. Id.
145. Id.
146. Id.
147. Id.
148. Id.
149. Id. “‘There is no drug, for anything, that gets to 95 percent,’ Kelly says. Plus, ‘it is cheap
and it is safe,’ says Lawrence Brandt, a professor of medicine and surgery at the Albert Einstein
College of Medicine, who has been performing the procedure since 1999.” Id.
150. Information About the Current Strain of Clostridium Difficile, CTRS. FOR DISEASE
CONTROL & PREVENTION, http://www.cdc.gov/HAI/organisms/cdiff/Cdiff-current-strain.html (last
updated 2010). “Over the past several years nationwide, states have reported increased rates of C.
difficile infection, noting more severe disease and an associated increase in mortality. C. diff
infection remains a disease mostly associated with healthcare (at least 80%). Patients most at risk
remain the elderly, especially those using antibiotics. Although the elderly are still most affected,
more disease has been reported in traditionally ‘low risk’ persons such as healthy person in the
community, and peripartum women.” Id.
151. McKenna, supra note 7.
152. Id.
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presents a startling economic cost.153 Studies estimate the daily cost of
C. diff treatment to be between $17.6 million and $51.5 million,154
bringing “the national cost of C. diff treatment between $1 billion and
$3.2 billion, conservatively.”155 These figures illustrate the need for an
effective, inexpensive treatment, which fecal transplants can fulfill.
Cases like Browning’s began to increase interest in FMT research.
In January 2013, the New England Journal of Medicine published the
results of a study that advocated for the use of fecal microbiota
transplants.156 The “52-patient study . . . compared the efficacy of
treatment with vancomycin, an antibiotic, and FMT in patients who
suffered from C. diff and had at least one relapse after antibiotics.”157
The study found that subjects who were suffering from C. diff had
decreased microbial diversity and introduction of healthy donor feces
increased the diversity, eliminating the C. diff. 158 This study also
emphasized that the best method for administering a fecal transplant
remains unknown.159 It explained, “Up until 1989, retention enemas had
been the most common technique for FMT. However, alternative
methods subsequently included fecal infusion via duodenal tube in 1991,
rectal tube in 1994, and colonoscopy in 1998.”160
In October 2013, a new method of performing a fecal transplant
was introduced: the pill form.161 A Canadian disease specialist, Dr.
Thomas Louie, performed a study on 31 patients suffering from C.
diff.162 Each subject took 24-34 capsules of fresh, healthy fecal bacteria,
coated in gelatin to maintain integrity in the stomach before reaching the

153. Syed Sayeed et al., Hospital-Acquired C. Difficile Infections, CONSUMERS UNION (Nov.
2008), http://consumersunion.org/pub/Final%20Cdiff%20Policy%20Brief%2011-11-08.pdf.
154. Id. “These figures do not take into account health care costs outside of the hospital or
nursing home, lost productivity, pain and suffering of patients or the time that medical professionals
must spend treating them.” Id.
155. Id.
156. Alexander J. Varond, Fecal Microbiota Transplantation: FDA Announces Limited
Enforcement Discretion, FDA L. BLOG (Jul. 23, 2013), http://www.fdalawblog.net/
fda_law_blog_hyman_phelps/2013/07/fecal-microbiota-transplantation-fda-announces-limitedenforcement-discretion.html.
157. Id.
158. Els van Nood et al., Duodenal Infusion of Donor Feces for Recurrent Clostridium
Difficile, 368 NEW ENG. J. MED. 407, 414 (Jan. 31, 2013), available at http://www.nejm.org/
doi/full/10.1056/NEJMoa1205037#t=articleBackground.
159. Id.
160. Bakken et al., supra note 124.
161. Sarah Zhang, Feces-Filled Pill Stops Gut Infection, SCI. AM. (Oct. 7, 2013),
http://www.scientificamerican.com/article.cfm?id=feces-filled-pill-stops-gut-infection.
162. Id.
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intestines intact.163 The pills cured 30 of the 31 patients.164 Dr. Louie
reported that lab-grown bacteria for the pills may be a future innovation,
and he is currently experimenting with freezing donor fecal matter for
later treatment.165 These studies not only provided a modern-day test of
the efficacy of fecal transplants, they also caught the attention of the
FDA.166
3. The FDA’s Attempt at Regulating Fecal Microbiota
Transplants
In early May 2013, the FDA held a workshop to “provide a forum
for the exchange of information, knowledge, and experience” regarding
fecal transplants.167 After gathering information from the workshop, the
FDA announced that it would require doctors who were performing fecal
transplants to submit an IND168 application prior to the procedure in
non-emergency situations.169 This new regulation did not affect clinical
trials because they were already subject to FDA approval.170 The FDA
guidelines provide that, “[o]nce the IND is submitted, the sponsor must
wait 30 calendar days before initiating any clinical trials. During this
time, the FDA has an opportunity to review the IND for safety to assure
that research subjects will not be subjected to unreasonable risk.”171
However, the FDA explained that physicians could obtain approval via
163. Id.
164. Id.
165. Id.
166. Varond, supra note 156.
167. Public Workshop: Fecal Microbiota for Transplantation, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/ucm34
1643.htm (last updated Mar. 10, 2014).
168. Investigational New Drug (IND) Application, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approv
alapplications/investigationalnewdrugindapplication/default.htm (last updated Oct. 27, 2014).
“Current Federal law requires that a drug be the subject of an approved marketing application before
it is transported or distributed across state lines. Because a sponsor will probably want to ship the
investigational drug to clinical investigators in many states, it must seek an exemption from that
legal requirement. The IND is the means through which the sponsor technically obtains this
exemption from the FDA. During a new drug’s early preclinical development, the sponsor’s primary
goal is to determine if the product is reasonably safe for initial use in humans, and if the compound
exhibits pharmacological activity that justifies commercial development. When a product is
identified as a viable candidate for further development, the sponsor then focuses on collecting the
data and information necessary to establish that the product will not expose humans to unreasonable
risks when used in limited, early-stage clinical studies.” Id.
169. Beth Mole, FDA Comes to Grips with Fecal Transplants, SCI. AM. (June 12, 2013),
http://www.scientificamerican.com/article.cfm?id=fda-comes-to-grips-with-fecal-transplants.
170. Id.
171. Investigational New Drug (IND) Application, supra note 168.
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phone or “other rapid means of communication” in an emergency.172
The move to regulate fecal transplants to ensure proper safety and
oversight met with strong criticism from physicians.173 Physicians
argued that “the added burdens of adhering to clinical trials regulations
would make the therapy more difficult, more expensive, more timeconsuming, and, ultimately, drive more patients to engage in do-ityourself fecal transplants.”174 This criticism caused the FDA to quietly
amend its previously issued guidelines regarding fecal transplants. In
July 2013, just one month after the FDA announced that it would require
IND applications from physicians, the FDA removed this requirement
altogether.175 “While maintaining its authority to require the submission
of an IND in some cases, [the FDA] would resort to a policy of
‘enforcement discretion’ under which it would allow most practitioners
to continue to conduct FMT procedures without an approved IND.”176
This “enforcement discretion” merely requires the physician to obtain
informed consent prior to performing a fecal transplant.177 The FDA
further instructed that the informed consent “should, at a minimum,
include a statement that the FMT product is still investigational and
involves assuming potential risks.”178
There are dangers associated with any procedure, and fecal
transplants are not exempt from this. Despite the apparent success of
FMTs, the procedure is still highly experimental. The human
gastrointestinal tract is filled with bacteria—good and bad—and can be
riddled with “viruses, fungi, protozoa and parasites.”179 There is a
possibility of transmitting “HIV, prion disease, e. coli 0157:H7, worms,
shigella, and other dysentery-causing infectious agents.”180 Since fecal
transplants did not undergo the rigors of clinical trials, the best method
172. Kristina Fiore, Fecal Transplant: FDA Wants Regulation, MED PAGE TODAY (May 15,
2013), http://www.medpagetoday.com/InfectiousDisease/GeneralInfectiousDisease/39169.
173. Alexander Gaffney, FDA Fast Tracks Fecal Transplant Product Intended to Treat
Clostridium Difficile Infections, REGULATORY FOCUS (June 25, 2013), http://www.raps.org/focusonline/news/news-article-view/article/3681.aspx.
174. Id.
175. Alexander Gaffney, Regulatory Approach for Fecal Transplant Product Finalized in
Abrupt Guidance Document, REGULATORY FOCUS (July 17, 2013), http://www.raps.org/focusonline/news/news-article-view/article/3795/regulatory-approach-for-fecal-transplant-productfinalized-in-abrupt-guidance-d.aspx.
176. Id.
177. Id.
178. Id.
179. Val Jones, Fecal Transplants: Getting to the Bottom of the Matter, SCIENCE-BASED MED.
(Nov. 27, 2008), http://www.sciencebasedmedicine.org/fecal-transplants-getting-to-the-bottom-ofthe-matter/.
180. Id.
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for receiving a transplant (pill, colonoscopy, enema or nasoduodenal
tube) and the best diluent (water or milk or other) are among the many
questions that remain unanswered.181 Thus, scholarship has concluded
that more research is required before FMTs “can be widely
advocated.”182
Furthermore, the loosening of restrictions regarding fecal
transplants illustrates that the FDA does not want to regulate areas where
new experiments are proving highly successful. Physicians continue to
experiment with conducting fecal transplants on patients while merely
obtaining informed consent.183 At least three Ohio hospitals routinely
offer the procedure to their patients.184 The success rate of fecal
transplants makes it tempting to view the new treatment as an exciting
innovation; there is, however, a fine line between innovation and
experimentation. The efficacy of fecal transplants came from “a long
series of successful case studies in the course of treatment, not clinical
trials.”185 Most fecal transplants were performed without IRB approval
or FDA oversight.186 It can be argued that there is never innovation
without experimentation, but this begs the question where should we
draw the line.187
D.

Comparing the Cases

These two cases—one involving fecal transplant and one involving
bacterial transplants in the brain—are similar because the bacterial
transplants in the brain were, and fecal transplants are, conducted
without FDA or IRB oversight. Both procedures are experimental and
require informed consent. Both procedures involve the novel concept of
transplanting microbiomes in hopes that they would colonize and
overcome the existing infection. The results, however, were strikingly
different. One must wonder, “[I]f [the bacterial transplants in the brain]
181. Judy Stone, The S**t Hits the Fan—FDA, INDs, and Fecal Microbiota Transplants, SCI.
AM. (May 20, 2013), http://blogs.scientificamerican.com/molecules-to-medicine/2013/05/20/the-sthits-the-fan-fda-inds-and-fecal-microbiota-transplants/.
182. Zain Kassam et al., Fecal Microbiota Transplantation for Clostridium Difficile Infection:
Systematic Review and Meta-Analysis, 108 AM. J. GASTROENTEROLOGY 500, 508 (2013).
183. Mole, supra note 169.
184. Suchetka, supra note 121.
185. Nicholson Price, Experiment vs. Innovative Treatment in Bacterial Transplants, BILL OF
HEALTH (Aug. 27, 2013), http://blogs.law.harvard.edu/billofhealth/2013/08/27/experiment-vsinnovative-treatment-in-bacterial-transplants/.
186. Id.
187. See generally Nancy M. P. King, The Line Between Clinical Innovation and Human
Experimentation, 32 SETON HALL L. REV. 573 (2002).
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had worked, would the reaction have been the same, or would the
surgeons have been hailed as innovators and heroes?”188
E.

The Reasonable Innovation Rule

Patients, however, would be safeguarded against unreasonable,
inadequately researched treatments suggested by physicians if the
reasonable innovation rule were codified. The doctors in the brain
bacteria case would not have been permitted to perform the procedure
under the reasonable innovation rule because adequate medical research
was not conducted prior to the experiment. The reasonable innovation
rule would set minimum standards higher than those required for
informed consent. If this rule were codified, doctors would assume a
larger role in providing reasonable treatment to their patients.
1. The Common Law Rule
The reasonable innovation rule states that, if customary care is
unlikely to provide an adequate treatment for a particular patient, a
doctor may reasonably innovate to meet the unique needs of the
patient.189 Everyday medicine requires physicians to exercise quick
decision-making skills, and therapeutic innovation is permissible when
customary care does not work for a patient.190 Each patient presents a
different challenge, and reasonable innovation is necessary to meet the
unique needs of each patient.191
2. The Scope of the Rule
It is important to identify the proper scope of a rule that fills the gap
between innovation and experimentation. The limits of the rule will be
illustrated by contrasting two cases where doctors implemented a new
technique with opposite results. The court in the Brook v. St. John’s
Hickey Memorial Hospital case, discussed in the following section, laid
out factors to determine what constitutes a reasonable innovation.192 The
court found the physician in that case had compelling professional
reasons for deviating from customary care by implementing an
innovation.193 First, he consulted medical journals and other professional
188.
189.
190.
191.
192.
193.

Price, supra note 185.
Brook v. St. John’s Hickey Mem’l Hosp., 380 N.E.2d 72, 76 (Ind. 1978).
Id.
Id.
Id.
Id.
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articles that warned against using customary care.194 Next, he
successfully implemented the innovation on other similar patients.195
Because of these two factors, the court concluded that his deviation from
the standard of care was reasonable.
a. Brook v. St. John’s Hickey Memorial Hospital
The first case illustrates how the reasonable innovation rule is
applied in practice. In Brook vs. St. John’s Hickey Memorial Hospital, a
specialist diagnosed a two-year-old with a possible urological
disorder.196 The specialist ordered X-rays taken with a contrast
medium197 to confirm the diagnosis.198 A radiologist injected the contrast
medium into the child’s calves because he was not able to find a vein in
which he could inject the medium.199 The contrast medium came in a
package accompanied by the manufacturer’s instructions for injection.200
The instructions specifically recommended that the medium be injected
into the gluteal muscles (buttocks).201 The radiologist, however, was
familiar with medical scholarship that warned against intramuscular
injection into the buttocks of young children because of the potential for
nerve and muscle damage.202 The doctor decided to inject the medium
into the child’s legs because “they were the next largest muscle mass
away from the trunk of the body.”203
194. Id. at 77.
195. Id.
196. Id. at 73.
197. “The contrast agent (also called contrast media, contrast material, X-ray dye, or
gadolinium contrast) shows up white on X-ray, CT, and MR images. This makes . . . organs, blood
vessels, and tissues more visible, which helps . . . interpret these imaging studies.” Contrast
OF
WASH.
MED.,
available
at
Injections
for
Imaging
Studies,
UNIV.
http://www.uwmedicine.org/services/radiology/Documents/Articles/Contrast_Injections_Imaging_S
tudies_2_10.pdf (last visited Feb. 16, 2015).
198. Brook, 380 N.E.2d at 73-74.
199. Id. at 74.
200. Id.
201. Id.
202. Id. The warning in the American Medical Association Journal specifically warned,
“anyone concerned with infants and children must be aware that injection into the buttock may
cause paralysis in the lower extremity. It is not often recognized that serious sciatic nerve injury can
result from intragluteal administration of therapeutic and prophylactic agents. Injection injury of the
sciatic nerve is more common than supposed and may be responsible for paralytic deformities
which may be misdiagnosed as congenital club feet or the sequelae of poliomyelitis. The newborn
infant, and especially the small premature infant, is more likely to suffer from this complication.
Any age group is vulnerable, and injury may result from a solitary injection. By abandoning the
intragluteal site and choosing another area for intramuscular injections, physicians may spare their
patients unnecessary handicaps.” Id. at 75.
203. Id. at 74.
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Four months after the injection, the child’s leg became stiff, and her
heel began to lift off of the ground.204 This problem was due to the
shortening of her Achilles tendon and may have been caused by the
intramuscular injection.205 Fortunately, after two operations and
extensive treatment, the child’s condition was “substantially
corrected.”206 The child’s parents, however, sued the radiologist, along
with the hospital and two other physicians, alleging that “[the
radiologist] was negligent in choosing an injection site which had not
been specifically recommended by the medical community and that this
choice of an unusual injection site was a medical experiment.”207 The
jury returned a verdict in favor of the radiologist,208 but the appellate
court reversed.209 The Indiana State Supreme Court then affirmed the
trial court’s judgment.210 In so doing, the Indiana Supreme Court
reasoned that the radiologist had several compelling reasons to choose
the calves as an injection site and deemed this method of injection a
therapeutic innovation rather than a negligent human experiment.211
Further, the court reasoned that the radiologist was not negligent
because he was trying to prevent the harm he had read about in journals
by choosing an injection site further away from the sciatic nerve.212
Additionally, the radiologist had used the injection site on other pediatric
patients in the past with no adverse reactions.213 The court warned that
“[t]oo often [other] courts have confused judgmental decisions and
experimentation. Therapeutic innovation has long been recognized as
permissible to avoid serious consequences.”214 Doctors should be
presumed to have the knowledge and skills to make judgments necessary
to treat their patients’ unique needs.215 The reasonable innovation rule
permits physicians to innovate in a limited scope if the patient is not
responding to customary care.216
204.
205.
206.
207.
208.
209.
210.
211.
212.
213.
214.
215.
216.
permitted
benefit of

Id.
Id.
Id.
Id. at 75.
Id. at 74.
Id.
Id. at 77.
Id. at 76.
Id. at 75.
Id. at 76.
Id.
Id.
Id. “(E)ven where there is an established mode of treatment, the physician may be
to innovate somewhat if he can establish that, in his best judgment, this was for the
his patient and where the established modes of treatment have proved unsuccessful.” Id.
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b. Felice v. Valleylab, Inc.
Felice v. Valleylab, Inc., by contrast, demonstrates that the
reasonable innovation rule holds physicians accountable when they fail
to follow reasonable practices. In that case, a two-year-old child
complained of pain during urination.217 A physician diagnosed the child
with phimosis218 and recommended a circumcision.219 Dr. Goodger, a
first-year family practice resident, and Dr. Glass, a third-year surgery
resident, were the only doctors present at the surgery.220 Dr. Glass
instructed Dr. Goodger to perform the circumcision using the guillotine
technique.221 Dr. Glass further instructed Dr. Goodger to use the
Valleylab Electrosurgical Unit (“ESU”) to perform the procedure.222
ESU “operates by applying a high frequency electrical current through a
‘surgical pencil’ to the cutting area.”223 The doctors had cut one-third the
distance across the foreskin when they realized something was wrong.224
The child’s penis retracted and became very pale, and the doctors soon
determined that he had sustained a full thickness burn225 from “excess
electrical current running through the penis.”226 The physicians removed
the remaining foreskin with scissors, sutured by hand, and applied burn
cream to the child’s penis.227 Just a few days later, the child developed a
high fever and was taken back to the hospital.228 When he arrived,

at 76, n.1
217. Felice v. Valleylab, Inc., 520 So. 2d 920, 922 (La. Ct. App. 1987).
218. “Phimosis is a constriction of the opening of the foreskin so that it cannot be drawn back
over the tip of the penis. This condition is a normal occurrence in the newborn boy, but over time,
the skin that adheres to the tip of the penis can be retracted as the foreskin loosens. By age 17, 99
percent of males will be able to completely retract their foreskin.” Phimosis and Paraphimosis in
Children, BOSTON CHILDREN’S HOSP., http://www.childrenshospital.org/health-topics/conditions/
p/phimosis-and-paraphimosis#sthash.9Q995J7v.dpuf (last visited Feb. 16, 2015).
219. Felice, 520 So. 2d at 922.
220. Id. at 923.
221. Id. “In this technique the foreskin of the penis is stretched past the end of the penis and
clamped with a hemostat to hold the foreskin in a position to be cut off. After the excess foreskin is
cut away, the bleeding is controlled and the edges of the foreskin are sutured together. Generally the
cutting in circumcisions is performed with a scalpel.” Id.
222. Id.
223. Id.
224. Id.
225. Id. “A third-degree burn is referred to as a full thickness burn. This type of burn destroys
the outer layer of skin (epidermis) and the entire layer beneath (or dermis).” Third Degree Burns,
CHILDREN’S HOSP. OF WIS., http://www.chw.org/display/PPF/DocID/21911/router.asp (last visited
Nov. 18, 2013).
226. Felice, 520 So. 2d at 923.
227. Id.
228. Id.
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doctors discovered that his penis was completely gone.229
The child’s parents sued the Department of Health and Human
Resources, based on respondeat superior, as well as the hospital for
negligent training and supervision.230 Valleylab was also named as a
defendant for failure to warn of the dangers of the ESU device.231 The
court found the state to be 100% at fault and awarded damages to the
child and his family.232 The court reasoned that Dr. Glass was
responsible for Dr. Goodger, but she simply assumed that Dr. Goodger
had the requisite training and experience to perform a circumcision using
the guillotine method with the ESU.233
Dr. Glass admitted that she had never been trained to use an ESU to
perform circumcisions in medical school, and in fact, she started using
this method only one week prior to the child’s procedure.234 Dr. Glass
had spoken with another resident about the possible benefits of a
circumcision performed with an ESU, and then she had used that
procedure on another patient with no adverse effects.235 The court noted
that Dr. Glass did not inquire with her supervising doctors about the use
of an ESU during circumcision.236 She did not read any medical
literature or review the ESU manual for any warnings regarding using
the device for circumcision.237 The patient did not even present a unique
need that required a deviation from the standard practice for
circumcision.238 Instead, “Dr. Glass merely decided to try it and see what
effect the ESU would have upon the surgery, since she considered it an
improvement upon well-established technique.”239 Because of these
lapses in the standard of care expected in a procedure like this, and
because Dr. Glass modified a familiar technique without adequately
researching its potential adverse effects, the court found the state was
vicariously responsible for her negligence.240
229. Id.
230. Id.
231. Id.
232. Id. at 929.
233. Id. at 928.
234. Id.
235. Id.
236. Id.
237. Id.
238. Id. at 929.
239. Id. at 928.
240. Id. at 928-29. “A hospital would be liable for the negligent act of a physician, nurse or
any other ‘employee’ acting within the scope of his employment for the hospital under the doctrine
of respondeat superior. In effect, the hospital is vicariously liable for the acts of its agent, servant or
employee, whether he be physician, nurse, or technician where they have engaged in a negligent act
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3. Comparing the Cases
Comparing these two cases illustrates the scope of the reasonable
innovation rule. The Felice case is similar to the Brook case because
both physicians deviated from the standard of care in their area.241 Both
doctors believed they were improving on established techniques to
enhance their patients’ care.242 The Felice case, however, radically
differs from the Brook case because use of the ESU was not considered a
reasonable innovation.243 In the Felice case, the patient did not present a
unique need that required innovation and deviation from established
standards of care.244 Furthermore, Dr. Glass failed to adequately research
the procedure.245 She did not consult her supervising doctors and did not
reference medical literature to explore potential consequences of what
she thought was an innovative procedure.246 Additionally, she had
performed the technique on only one other patient before deciding to
implement the technique regularly.247 The gross deviation from
customary care was a human experiment that left a boy permanently
disfigured. The Brook case, on the other hand, illustrates the potential for
appropriate innovation under the reasonable innovation rule: a doctor
adequately researching and implementing an innovative, but reasonable,
procedure based on a patient’s unique needs.
The reasonable innovation rule is essential to medicine because we
do not want to curb doctors’ new methods, ideas, and procedures, but we
do want to protect the patient. Without innovation, the medical field
would become stagnant, and we would not see the growth that
innovation provides to the field.248 Each patient presents unique needs,
and these needs can be met through reasonable innovation.249

within the scope of their employment.” PEGALIS, supra note 2, § 6:20.
241. See Brook v. St. John’s Hickey Mem’l Hosp., 380 N.E.2d 72, 77 (Ind. 1978); Felice, 520
So. 2d at 928.
242. Brook, 380 N.E.2d at 74; Felice, 520 So. 2d at 928.
243. See Felice, 520 So. 2d at 928-29 (discussing reasonable innovation).
244. Id. at 929.
245. Id. at 928.
246. Id.
247. Id. at 928.
248. Philip D. Noguchi, From Jim to Gene and Beyond: An Odyssey of Biologics Regulation,
51 FOOD & DRUG L.J. 367, 372 (1996).
249. Id.
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Why the Reasonable Innovation Rule Should be Codified:
Balancing the Interest of Innovation with the Protection of Patient
Safety

The reasonable innovation rule must be codified because it
successfully balances the interests of the law, physicians, patients, and
innovation. First, the law will benefit from codification because the rule
will no longer be hidden in case law. If the FDA codifies this rule, it will
be concrete and accessible as a regulation. Informed consent will no
longer be the minimum standard. The shortcomings and problems with
obtaining true informed consent will be addressed because the physician
will assume a shared responsibility in the medical decision-making
process. The physician will be held to a standard of implementing only
reasonable innovations. Having a reasonable standard balances the
physician’s interest in trying to save her patient by any means possible
with what is reasonable based on the patient’s unique needs.
Physicians will benefit from the codification of the reasonable
innovation rule because their personal autonomy will be preserved. The
rule is not so stringent as to eliminate freedom to deviate from common
practices. It instead raises the minimum standard from being able to
implement any procedure with informed consent to being able to
implement any reasonable procedure. This will encourage researchers to
focus on treatments that demonstrate success, like fecal transplants,
while ensuring that physicians introduce only well-researched treatments
to patients. Physicians will still find enjoyment and professional
fulfillment in the latitude they are given in the decision-making process.
Their knowledge, skills, training, and experience will be honored; their
judgment, trusted.
Patients will also benefit from codification of the rule. When
patients are in a dire situation that makes them more likely to consent to
dangerous novel treatments, the rule will provide an extra safeguard. The
physician will be required to implement only what is reasonable, and
patients can fully trust their doctor’s decisions. This will prevent results
like those in the bacterial transplant case, where the physicians felt that
they could side-step FDA regulations after obtaining their patients’
informed consent. Thus, the solidarity of the patient-physician
relationship (which is already quite strong)250 will increase because the
rule will foster trust.
Finally, the interest of medical innovation and growth will be

250.

Patient Consent, supra note 71.
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preserved if the rule is codified. The rule recognizes that innovation is
part of the medical profession and without innovation growth would be
stunted. Innovative treatment based on the unique needs of the patient
will still be permitted. This rule, however, will protect against
unreasonable, poorly researched innovations not yet fit for human
implementation regardless of whether patients have consented.
G.

Proposed Language for Codification

The following language is proposed for codification:
A physician may innovate if it is reasonable under the
circumstances. The decision to innovate should be driven by the unique
needs of the individual patient that cannot be met by customary practice.
If the physician seeks to incorporate the innovation into daily practice
involving all patients, the physician must first obtain permission from
the IRB in the hospital where the innovative procedure will occur or, if
the procedure will not occur in a hospital, a stand-alone IRB.
Under this standard, the question of “reasonableness” is left to the
jury to determine. Ideally, the jury will consider the same factors as in
the Brook case: whether the doctor sufficiently researched the innovation
by consulting professional literature prior to implementation , and
whether there was evidence of prior success based on other patients.
V. CONCLUSION
Codification of the reasonable innovation rule will help avoid
tragedies like the deaths of the three patients who consented to bacterial
injections out of desperation. Under the proposed reasonable innovation
rule, the patients’ consent would not have been enough to commence the
procedure. Instead, the physician would have had an obligation to
implement only what was reasonable based on extensive research.
Implementing the reasonable innovation rule would have prevented the
physicians from circumventing FDA protocol. It recognizes that even
physicians may be blinded by their desire to do whatever possible to
save their patients. While this desire is admirable, it demonstrates the
need for a minimum standard in the decision-making process.
The reasonable innovation rule will also foster innovation, as
evidenced by the fecal transplant cases. This procedure, while not
extensively studied in clinical trials, could be deemed reasonable based
on the surrounding facts and evidence. The patients who underwent the
fecal transplants presented a unique need that was not being met by
customary practices. Novel innovations such as this are crucial, and the
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rule will not curb the use of such treatments. Deeming an innovative
treatment objectively reasonable is an important part of deciding
whether to advise patients to undertake the potential risks of any given
procedure.
The FDA should codify the reasonable innovation rule because of
these reasons. The medical and legal professions, as well as society as a
whole, will greatly benefit from the rule’s codification. Most
importantly, human experimentation masked as innovation will be
reduced by codification of the rule.
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